Fisetin induces g2/m phase cell cycle arrest by inactivating cdc25c -cdc2 via atm-chk1/2 activation in human endometrial cancer cells

5Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Endometrial cancer is one of the most prevalent gynaecological malignancies where, currently available therapeutic options remain limited. Recently phytochemicals are exploited for their efficiency in cancer therapy. The present study investigates the anti-proliferative effect of fisetin, a flavonoid on human endometrial cancer cells (KLE and Hec1 A). Fisetin (20-100 μM) effectively reduced the viability of Hec1 A and KLE cells and potentially altered the cell population at G2/M stage. Expression levels of the cell cycle proteins (cyclin B1, p-Cdc2, p-Cdc25C, p-Chk1, Chk2, p-ATM, cyclin B1, H2AX, p21 and p27) were analyzed. Fisetin suppressed cyclin B1 expression and caused inactivation of Cdc25C and Cdc2 by increasing their phosphorylation levels and further activated ATM, Chk1 and Chk2. Increased levels of p21 and p27 were observed as well. These results suggest that fisetin induced G2/M cell cycle arrest via inactivating Cdc25c and Cdc2 through activation of ATM, Chk1 and Chk2.

Cite

CITATION STYLE

APA

Wang, Z. Y., Liu, W. Q., Wang, S., & Wei, Z. T. (2015). Fisetin induces g2/m phase cell cycle arrest by inactivating cdc25c -cdc2 via atm-chk1/2 activation in human endometrial cancer cells. Bangladesh Journal of Pharmacology, 10(2), 279–287. https://doi.org/10.3329/bjp.v10i2.21945

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free